Pharmacokinetics, Pharmacodynamics and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17 mg per day. Cov...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Ther
Autors principals: Kim, Hanna, Brooks, Kristina M., Tang, Cheng Cai, Wakim, Paul, Blake, Mary, Brooks, Stephen R., Sanchez, Gina A. Montealegre, de Jesus, Adriana A., Huang, Yan, Tsai, Wanxia Li, Gadina, Massimo, Prakash, Apurva, Janes, Jonathan Marcus, Zhang, Xin, Macias, William L., Kumar, Parag, Goldbach-Mansky, Raphaela
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089664/
https://ncbi.nlm.nih.gov/pubmed/29134648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.936
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars